The role of apoptosis in the development of AGM hematopoietic stem cells revealed by Bcl-2 overexpression by Orelio, C. et al.
HEMATOPOIESIS
The role of apoptosis in the development of AGM hematopoietic stem cells
revealed by Bcl-2 overexpression
Claudia Orelio, Kirsty N. Harvey, Colin Miles, Robert A. J. Oostendorp, Karin van der Horn, and Elaine Dzierzak
Apoptosis is an essential process in em-
bryonic tissue remodeling and adult tis-
sue homeostasis. Within the adult hema-
topoietic system, it allows for tight
regulation of hematopoietic cell subsets.
Previously, it was shown that B-cell leuke-
mia 2 (Bcl-2) overexpression in the adult
increases the viability and activity of he-
matopoietic cells under normal and/or
stressful conditions. However, a role for
apoptosis in the embryonic hematopoi-
etic system has not yet been established.
Since the first hematopoietic stem cells
(HSCs) are generated within the aorta-
gonad-mesonephros (AGM; an actively
remodeling tissue) region beginning at
embryonic day 10.5, we examined this
tissue for expression of apoptosis-
related genes and ongoing apoptosis.
Here, we show expression of several pro-
apoptotic and antiapoptotic genes in the
AGM. We also generated transgenic mice
overexpressing Bcl-2 under the control of
the transcriptional regulatory elements of
the HSC marker stem cell antigen–1 (Sca-
1), to test for the role of cell survival in the
regulation of AGM HSCs. We provide evi-
dence for increased numbers and viabil-
ity of Sca-1 cells in the AGM and subdis-
sected midgestation aortas, the site where
HSCs are localized. Most important, our
in vivo transplantation data show that
Bcl-2 overexpression increases AGM
and fetal liver HSC activity, strongly
suggesting that apoptosis plays a role in
HSC development. (Blood. 2004;103:
4084-4092)
© 2004 by The American Society of Hematology
Introduction
The hematopoietic system of adult mammals has its foundation in
rare hematopoietic stem cells (HSCs) harbored in the bone marrow
(BM). These cells are highly potent, contributing to the billions of
mature hematopoietic cells in the blood and hematopoietic tissues
throughout the lifetime of the individual.1,2 In the mouse embryo,
the first HSCs are autonomously generated in the aorta-gonad-
mesonephros (AGM)3 region. The onset of HSC activity occurs at
embryonic day 10.5 (E10.5) in the AGM, and HSC activity
increases from E11 until E14 in the liver.3-7 Thereafter, the number
of HSCs generally remains constant throughout life.8,9
The signals and processes by which HSCs are generated,
expanded, and/or maintained in embryonic, fetal, and adult stages
are largely unknown. The fact that HSC numbers increase signifi-
cantly in the midgestation mouse, while remaining constant in the
adult, suggests that there are differences in the processes control-
ling HSC numbers at different times in ontogeny.3,5 Although
temporally limited hematopoietic cell fate determination processes
and HSC proliferation may be primarily responsible for increasing
numbers of HSCs in the midgestation embryo, it is possible that the
balance between programmed cell death and survival plays an
additional role in the quantitative increase in HSCs.
Programmed cell death, or apoptosis, is a highly conserved
process involved in adult tissue homeostasis (as reviewed Evan and
Littlewood10 and Meier et al11) and, within embryos in the
remodeling of the limbs, kidney, and other structures.11,12 Important
regulators of apoptosis are the B-cell leukemia 2 (Bcl-2) family of
proteins; the proapoptotic Bcl-2–associated X (Bax) and Bcl-2
homology 3 (BH3) subfamilies (which includes Bcl-2 interacting
mediator of cell death [Bim]), and the antiapoptotic Bcl-2 subfam-
ily (including Bcl-2 and Bcl-x), which promotes cell survival.13 It is
thought that proapoptotic and antiapoptotic proteins counteract
each other’s function via protein-protein interactions (reviewed in
Bouillet et al14 and Strasser et al15). Hence, appropriately controlled
temporal and spatial expression of proapoptotic and antiapoptotic
proteins is a prerequisite for normal tissue development.11,16-18
Within the adult hematopoietic system, Bcl-2 and Bcl-x are
expressed in immature hematopoietic and lymphoid cells (espe-
cially mature thymocytes).19-23 Overexpression of Bcl-2 in T cells
increases cell survival and decreases negative selection,24-26 suggest-
ing a role for Bcl-2 in the thymocyte selection process. Apart from
the lymphoid system, the role of apoptosis in the regulation of
hematopoietic progenitor and stem cells is far less understood. A
number of studies have investigated the role of apoptosis in adult
BM HSCs using transgenic mouse models in which Bcl-2 overex-
pression is directed with the use of the hematopoietic specific vav
promoter27 or by use of the more general/ubiquitous H-2K pro-
moter.9,28 In both cases, overexpression of Bcl-2 within the
HSC/hematopoietic progenitor compartment resulted in enhanced
cell survival and radio-resistance of these cells.9,27,28 However,
these studies were limited to the analysis of adult and fetal
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hematopoietic cells and did not study the effects of Bcl-2 overex-
pression in AGM HSCs.
Since extensive tissue remodeling is ongoing in the AGM region at
the time when HSCs first emerge within the midgestation mouse
embryo, we set out to specifically analyze apoptosis in AGM HSCs. We
show here, within the midgestation AGM and more specifically the
aorta, that both proapoptotic and antiapoptotic genes are normally
expressed as the AGM is generating HSCs. To further investigate the
role of apoptosis in HSC development, we specifically directed overex-
pression of Bcl-2 to HSCs in the AGM using the transcriptional control
elements of the commonly used stem cell antigen–1 (Sca-1) HSC
marker.29,30 We have previously demonstrated that these Sca-1 (Ly-6E/A)
control elements faithfully express reporter genes in the first functional
repopulating HSCs from the midgestation dorsal aorta (the specific
AGM site of the first emerging HSCs).31-35 Here we show that
Ly-6E/A–directed Bcl-2 overexpression results in increased numbers of
Sca-1 and c-kit cells in the AGM, in increased survival of AGM
HSCs, and, most importantly, in increased AGM HSC activity. These
data strongly suggest that apoptosis plays an important role in the
regulation of HSCs beginning at the earliest stages of HSC development
in the AGM.
Materials and methods
Generation of transgenic mice
An 865-bp murine Bcl-2 cDNA fragment36 was inserted in the Ly-6E
expression cassette.31,37,38 The 14.9-kb NotI linearized fragment was
microinjected into (CBA  C57BL/10)F1 oocytes. Out of 17 founder mice
born, 6 transmitted the transgene, and 2 lines were used for further studies.
Bcl-2 transgenic mice appeared normal, and the total body weight was
unchanged from that of the wild-type littermates (Table 3). Matings were set
up between Bcl-2 transgenic males and (CBAC57BL/10)F1 females. The day
of the vaginal plug was counted as day 0. Pregnant mice were killed by cervical
dislocation, and embryos were collected in phosphate-buffered saline (PBS)/10%
fetal calf serum (FCS).Animals were housed according to institutional guidelines
(Experimental Dieren Centrum, Erasmus University Medical Center), and
animal procedures carried out in compliance with the Standards for Humane Care
and Use of Laboratory Animals.
Genotyping, copy number determination,
and expression analysis
For Bcl-2 and YMT genotyping (myogenin [Myo] control), polymerase
chain reaction (PCR) conditions were as follows: 100 to 200 ng DNA; 100
ng each primer (Table 1); 1  buffer; 0.2 mM deoxynucleoside triphos-
phate (dNTP); and 1 U AmpliTaq (Applied Biosystems, Foster City, CA),
with cycling for 5 minutes at 92°C, 30  (40 seconds at 92°C, 40 seconds at
60°C, 1 minute at 72°C), and 7 minutes at 72°C.
For copy number analysis, a Southern blot with 10 to 20 g
HindIII-digested genomic DNA was probed with a nick-translated (Amer-
sham Pharmacia Biotech, Piscataway, NJ) 32P-labeled 865-bp Bcl-2 frag-
ment. Analysis was performed by phosphorimaging (Molecular Dynamics,
Piscataway, NJ) and ImageQuant software (Amersham Pharmacia Biotech).
For Northern blot analysis, 20 g RNA isolated from several tissues
with TRIZOL (Invitrogen/Life Technologies, Carlsbad, CA) was blotted
against Genescreen membrane (NEN Life Science Products, Boston, MA).
The blot was probed with a 32P-labeled 865-bp Bcl-2 cDNA fragment. Ly6
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes are as
described previously.31
For reverse-transcription PCR (RT-PCR) analysis, embryos were (sub)
dissected and tissues stored in RNAlater (Ambion, Austin, TX) at 4°C.
Embryos were genotyped, and tissues from similar genotypes were pooled
and homogenized in TRIZOL. RNA was isolated according to manufactur-
ers’ instructions. We used 1 to 5 g DNase-treated RNA (RQ1 RNase free
DNase; Promega, Madison, WI) for cDNA synthesis with Superscript II
Reverse Transcriptase (Invitrogen/Life Technologies). RT-PCR was per-
formed in a 50-L vol with 100 ng each primer (Table 1), 0.2 mM dNTP,
AmpliTag, and buffer (Perkin Elmer, Shelton, CT), together with a 40 to
100 ng RNA equivalent of cDNA. Cycling conditions were as follows: 5
minutes at 92°C; 28 to 30  (40 seconds at 92°C, 40 seconds at 58°C, 1
minute at 72°C); and 7 minutes at 72°C. PCR products were run on 1.2%
agarose/1 Tris-borate-EDTA (tris(hydroxymethyl)aminomethane-borate–
ethylenediaminetetraacetic acid) (TBE) gels with ethidium bromide (EtBr)
and scanned on a Typhoon scanner (Molecular Dynamics).
For Western blot analysis, protein extracts from several adult tissues
were made in Laemmli buffer, separated on a 10% sodium dodecyl sulfate
(SDS) polyacrylamide gel, and blotted to polyvinylidene difluoride (PVDF)
membrane (Millipore, Billerica, MA). Blots were blocked and incubated
with an anti–Bcl-2 antibody (Alexis Biochemicals, San Diego CA) in 2%
milk/Tris–buffered saline–Tween (TBS-T) followed by an antirabbit–
horseradish peroxidase (HRP) antibody (DAKO, Carpinteria, CA) and
enhanced chemiluminescence (ECL) detection.
Survival and cell viability assays
Healthy transgenic and nontransgenic littermates mice of 7 to 13 (Ln 2) and
8 to 22 (Ln 479) weeks of age were randomly divided into 3 pools, which
received equal split doses of 10.5, 9.5, or 8.5 Gy -irradiation. Mice
received antibiotics and were checked daily for survival.
Whole BM cells from Bcl-2 transgenic and nontransgenic littermates
were collected in PBS/10% FCS, suspended as single cells, and counted
(Beckman Coulter, Fullerton, FL). BM cells were seeded at a cell density of
2  105/mL in Dulbecco Modified Eagle medium (DMEM)/10% FCS/
Table 1. Primer sequences
Primer Primer sequence, 53 3
Sequence or reference
on which this was based
PCR fragment
length, bp
BC2PE GTGCAGCTGACTGGACATCTCTGC Miles et al31; Negrini et al39 450
PE5 ACTCTGCCTGCAACCTTGTCTGAG Miles et al31; Negrini et al39 450
YMT2-1 CTGGAGCTCTACAGTGATGA Medvinsky and Dzierzak3 342
YMT2-2 CAGTTACCAATCAACACATCAC Medvinsky and Dzierzak3 342
Myo-1 TTACGTCCATCGTGGACAGC Mu¨ller et al4 245
Myo-2 TGGGCTGGGTGTTAGTCTTA Mu¨ller et al4 245
mBcl-2 forward GCACAGATGTCCAGTCAGCTG NM_009741 268
mBcl-2 reverse GCCATATAGTTCCACAAAGGC NM_009741 268
mBcl-x forward GGCGATGAGTTTGAACTGCG U51278 915
mBcl-x reverse CCTCACTCAATGGCTCTTGG U51278 915
mBim forward GAGAAGGTGGACAATTGCAG AF032461 290, 380
mBim reverse GCCTTCTCCATACCAGACGG AF032461 290, 380
beta-actin forward CCTGAACCCTAAGGCCAACCG X03672 398
beta-actin reverse GCTCATAGCTCTTCTCCAGGG X03672 398
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penicillin (Pen)/streptomycin (Strep) at 37°C, 5% CO2. At 1, 2, 4, 8, and 11
days, viable cell counts were determined by trypan blue exclusion.
FACS analysis, immunostaining, and TUNEL staining
AGM and liver tissues were dissected, and explant cultures for 3 to 4 days
were performed as described previously.3,5 During the culture period,
embryos were genotyped, and tissues with similar genotypes pooled.
Before staining, tissues were collagenase treated as described. BM cells
were made directly into a single-cell suspension. Cell staining was done in
PBS/10% FCS with fluorescein isothiocyanate (FITC)– or phycoerythrin
(PE)–conjugated antibodies against Sca-1, c-kit, CD4, CD8, CD11b
(macrophage antigen–1 [Mac-1]), Ly-6G(Gr1), B220, and annexin V
(Pharmingen, Franklin Lanes, NJ), and fluorescence was measured on a
FACScan or FACSVantage (Becton Dickinson, Franklin Lanes, NJ). Dead
cells were excluded by 7-amino-actinomycin D (7AAD) or Hoechst 33258
(Molecular Probes, Eugene, OR) staining.
For immunofluorescence, single-cell suspensions from AGM cells from
Ly6A–green fluorescent protein (GFP) embryos were made. Cytospin cells
were fixed (2% paraformaldehyde/PBS) and stained with Bcl-2 antibody
and -rabbit–Texas Red or cyanine 3.18 (Cy3) secondary antibody.
Embryos were frozen in Tissue-Tek (Sakura Finetek USA, Torrance,
CA) and cryosectioned (7-8 M). transferase-mediated deoxyuridine
triphosphate nick end labeling (TUNEL) staining was performed with the in
situ cell death detection kit/peroxidase (POD) (Roche, Indianapolis, IN) on
the basis of the manufacturer’s instructions. Staining was visualized with
peroxidase substrate AEC (3-amino-9-ethylcarbazde), and sections were
dehydrated and embedded in Entallan (Merck, West Point, PA).
In vivo repopulation assays for HSCs
For all transplantations, male donor cells were injected intravenously into
(CBA  C57BL/10)F1 females irradiated with a 9.5-Gy split dose of
-irradiation. Repopulation was assayed at 1 and 4 months after transplanta-
tion by a Y-chromosome (YMT)–specific PCR on peripheral blood DNA.
Multilineage repopulation was analyzed on several recipients either by PCR
on DNA from hematopoietic tissues or as described previously.40
Donor male Bcl-2 transgenic and nontransgenic littermates (10 weeks
old) were killed, and BM cells collected and injected into recipients at
several cell doses in combination with 105 female competitor BM cells. For
repopulation assays on E11 and E12 AGM and liver cells, tissues were
dissected and collagenase treated (0.125%) in PBS/10% FCS. Then, 0.3
embryo equivalents (ee) AGM cells (approximately 2  105/ee for E11;
approximately 3  105/ee for E12) or 0.03 to 0.003 ee liver cells
(approximately 3  106/ee for E12) were injected with 2  105 female
spleen cells into recipients. For secondary transplantations, BM was
collected from reconstituted primary recipients, and 105 cells were injected
into secondary recipients. Secondary recipients receiving BM from primary
recipients injected with E12 AGM or liver were coinjected with 105 female
BM cells.
Results
Expression of proapoptotic and antiapoptotic regulators
in the midgestation aorta
To date, little is known concerning the expression of proapoptotic
and antiapoptotic regulators in the midgestation AGM region and
particularly HSCs. To examine whether apoptosis normally occurs
in the AGM, TUNEL analysis was performed on transverse
sections through the truncal regions of midgestation embryos.
Several TUNEL foci are found scattered throughout the represen-
tative E11 truncal section shown in Figure 1A. In the AGM region,
many highly positive foci are found in the mesonephic tubules of
the urogenital ridges (UGRs), while only one strongly positive
focus was found a short distance from the dorsal side of the dorsal
aorta (Figure 1B). However, many diffuse individually weak
TUNEL cells are also found surrounding the dorsal aorta,
suggesting that apoptotic processes are occurring throughout the
AGM region during midgestation.
The expression of antiapoptotic genes Bcl-2 and Bcl-x and the
proapoptotic gene Bim in the whole AGM, aorta, UGRs, and liver
was examined by semiquantitative RT-PCR. As shown in Figure
1C, Bcl-2 expression is approximately 2-fold higher in the E11
AGM as compared with the E11 liver. Similar results were obtained
with E12 tissues (not shown). In the E11 AGM, Bcl-2 is expressed
in both the aorta and the UGR, with a higher level of expression in
the UGR. Bcl-x and Bim expression levels are comparable in the
E11 AGM, and liver, with Bim expression appearing to be slightly
higher in the UGR than in aorta. Thus, both antiapoptotic and
proapoptotic genes are expressed in the embryonic sites (aorta and
liver) harboring the earliest HSCs.
To determine if Bcl-2 is normally expressed in AGM HSCs,
immunostaining was performed on cytospins of E12 Ly-6A (Sca-1)
GFP transgenic AGM cells. Previous studies in such transgenic
embryos31-35 have shown that all AGM HSCs are GFP. When we
performed Bcl-2–specific antibody staining on such cytospins, we
observed Bcl-2 expression in many AGM cells (Figure 2C), among
which are GFP cells (Figure 2B). AGM GFP cells include aortic
HSCs and endothelial and mesonephric tubule cells.34 Overlay of
the 2 fluorescent signals shows that the GFP cells coexpress the
Bcl-2 protein (Figure 2D). To exclude the GFP mesonephric cells,
cytospins from subdissected E11 aortas were immunostained with
the Bcl-2 antibody. Figure 2F-H shows expression of Bcl-2 in all
GFP cells, which include only HSCs and endothelial cells. Bcl-2
Figure 1. Apoptotic foci and apoptosis-related gene expression in the E11 AGM.
TUNEL staining was performed on transverse sections from the truncal region of an
E11 embryo to localize apoptotic cells in the AGM region. (A-B) A representative
section is shown at 10  magnification (A) and at 40  magnification (B). TUNEL
(black/gray) foci and diffuse scattered individual cells are observed. DA indicates
lumen of dorsal aorta; UGR, urogenital ridge; M, mesentery. TUNEL staining was
performed 3 times on 2 wild-type and 2 Bcl-2 transgenic embryos. No obvious
difference in the TUNEL staining pattern was observed when sections from Bcl-2
transgenic embryos were compared to sections from nontransgenic embryos.
(C) Expression of the antiapoptotic genes Bcl-2 and Bcl-x and the proapoptotic Bim
gene in the E11 AGM, aorta, UGRs, and liver region of a nontransgenic embryo.
RT-PCR analysis was performed on cDNAs made from the indicated midgestation
tissues. Signal intensity from the actin PCR fragment was used as a normalization
control. Note that, as expected, the Bim primers amplify 2 different transcript isoforms
(splice variants). (D) RT-PCR analysis of a Bcl-2 transgenic embryo reveals altered
levels of Bcl-2, Bcl-x, and Bim gene expression in the E11 aorta and UGR. RT-PCR
analysis was performed 3 times and confirmed on 3 independent sets of cDNAs.
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expression in such cells was confirmed by RT-PCR analysis on
sorted c-kitAGM cells (c-kit is a marker for HSCs but not mesoneph-
ric cells)41 (not shown). Taken together, these data indicate that apoptosis
is taking place within the AGM and that Bcl-2 is expressed in aortic and
AGM HSCs and/or endothelial cells.
Sca-1 Bcl-2 transgenic mice overexpress Bcl-2 in
hematopoietic cells
To study whether apoptotic/cell survival processes are functional
within the embryonic hematopoietic system, we generated trans-
genic mice in which overexpression of the antiapoptosis gene Bcl-2
was directed by the Sca-1 (Ly-6E) transcriptional control elements.
A Bcl-2 cDNA fragment36 was inserted into the first untranslated
exon of the 14-kb Ly-6E genomic fragment31,38 (Figure 3A), and 2
transgenic lines (Ln 2 and Ln 479) were analyzed in detail. The
copy number was determined by Southern blot analysis, comparing
signal intensity of the endogenous 1.4-kb Bcl-2 gene fragment to
the 4.7-kb transgenic Bcl-2 band (Figure 3B). The transgene copy
numbers of Ln 2 and Ln 479 are 7 and 20, respectively. Northern
blot analysis demonstrated overexpression of the Bcl-2 transgene in
kidney, liver (Figure 3C), thymus, and spleen (data not shown).
Western blotting revealed that Bcl-2 protein expression was also
elevated in transgenic animals (Figure 3D). Only low or undetectable
levels of endogenous Bcl-2 protein were found in wild-type littermates,
consistent with low mRNA expression in the wild type. Thus, the Sca-1
transcriptional regulatory elements direct Bcl-2 expression at high levels
in several hematopoietic and nonhematopoietic tissues in the transgenic
animals, and this expression pattern correlates with the Ly-6E/A
expression pattern as previously reported.31-35
Bcl-2 overexpression results in radio-protection and increased
hematopoietic cell viability in the adult
To test the validity of our transgenic model, we examined the
effects of Bcl-2 overexpression in the adult hematopoietic system.
We performed survival experiments to assess whether Sca-1–
directed Bcl-2 overexpression could protect cells from radiation-
induced apoptosis in vivo. Transgenic animals and normal litter-
mates were challenged with different doses of total body
-irradiation, and the number of viable animals was determined
daily for up to 30 days. At doses of 10.5 (Figure 4A), 9.5, and 8.5
Gy (not shown), both Ln 479 and Ln 2 (not shown) transgenic
animals showed higher survival rates at day 30 in comparison with
their wild-type littermates.
To test whether this increased survival could be related to
protection of cells of the hematopoietic system from apoptosis, we
performed in vitro experiments using BM (Figure 4B) cells from
Bcl-2 transgenic and wild-type littermates. Over a period of 11
Figure 2. Expression of Bcl-2 by Sca-1 AGM cells. Immuno-
staining was performed on Ly-6A (Sca-1) GFP transgenic E12
AGM and E11 aortic cells. AGM and aorta cells were isolated as a
single-cell suspension and deposited on microscope slides by
cytospin (original magnification,  100). Panels A, E, and I show
4,6-diamidino-2-phenylindole (DAPI) staining; panels B, F, and J
show Ly-6A (Sca-1) GFP fluorescence; panel C shows anti–Bcl-2
Texas Red fluorescence; and panel G shows anti–Bcl-2 Cy3
fluorescence. Panel K was incubated with no primary antibody.
Panels D, H, and L are an overlay of GFP and Texas Red/Cy3
fluorescence. Panels A-D are a cytospin of E12 AGM cells stained
with anti–Bcl-2 antibody conjugated with Texas Red. Panels E-H
show a cytospin of E11 aorta cells stained with anti–Bcl-2 antibody
conjugated with Cy3. Panels I-L show a cytospin of E11 AGM cells
incubated with no primary antibody.
Figure 3. Overexpression of Bcl-2 in hematopoietic tissues of Sca-1 Bcl-2
transgenic mice. (A) Transgene construct. An 865-bp murine Bcl-2 cDNA fragment
was inserted into exon one of a 14-kb Sca-1 (Ly-6E) expression cassette. H indicates
HindIII. (B) Transgene copy number determination. A Southern blot containing
HindIII-digested DNA was probed with a Bcl-2 fragment to reveal the 1.4-kb
endogenous gene and 4.7-kb transgene. Ln 479 contains 20 and Ln 2 contains 7
copies of the transgene. (C) Northern blot analysis for Bcl-2 transgene expression in
several adult tissues. Bcl-2 is expressed in liver and kidney in Ln 479 and Ln 2 Bcl-2
transgenic (tg) animals. (D) Western blot analysis of Bcl-2 protein expression in Ln 2
and Ln 479 transgenic animals. Bcl-2 is overexpressed in several transgenic tissues,
including kidney, thymus, spleen, and bone marrow, as compared with nontransgenic
(wild-type [wt]) littermates. In general, no obvious abnormalities were found in the
transgenic adults. Blood smears showed no morphologic differences or leukemic
cells, and hematocrits did not differ between the transgenic and nontransgenic adults
(data not shown).
Bcl-2 OVEREXPRESSION AND AGM HEMATOPOIESIS 4087BLOOD, 1 JUNE 2004  VOLUME 103, NUMBER 11
days, in the absence of added hematopoietic growth factors, the
survival of nonadherent cells was determined. The number of
viable cells derived from Bcl-2 transgenic BM and spleen (not
shown) were much greater than those derived from wild-type
littermates. Hence, the increased survival rate of the Bcl-2 trans-
genic mice is due, at least in part, to increased viability of
hematopoietic cells.
We next examined whether the increased number of viable
cells in these cultures was due to decreased apoptosis by flow
cytometric analysis with annexin V (an early marker of apopto-
sis) and 7AAD staining42 (Table 2). Nontransgenic cells cultured
under the stressful hematopoietic growth factor–free conditions
showed the expected pattern of cell death, with 31% of cells in
the nonviable (7AAD) quadrants. In contrast, Bcl-2 transgenic
cultures showed only 4% 7AAD cells, with a much higher
percentage of cells in a viable state (91% annexin7AAD). The
percentage of cells in the early stages of apoptosis
(annexin7AAD) was almost 3-fold higher in the nontrans-
genic cultures as compared with the Bcl-2 transgenic cultures.
Thus, Bcl-2 overexpression decreases the number of BM cells
entering into apoptosis in growth factor–free hematopoietic
cultures, resulting in increased numbers of viable cells.
To investigate whether lower apoptosis/higher cell maintenance
was occurring in Bcl-2 transgenic hematopoietic cell subsets that
normally express Sca-1,43 we examined T- and B-lymphoid cells in
the thymus and spleen (Table 3). Increases in the percentages of
CD4CD8, CD4, and CD8 thymocytes and a concomitant
large decrease in CD4CD8 thymocytes are observed in trans-
genic adults (Table 3). Also, the absolute number of mature CD4
and CD8 T cells in the spleen are increased (2.5- to 4-fold), and a
2- to 3-fold increase in the absolute number of B220 splenocytes
is observed. Taken together, the increases in the absolute number of
spleen cells (approximately 17-25  107) can be accounted for by
the increase in the mature lymphocyte CD4, CD8, and B220
subsets and may be attributed to increased cell survival by
overexpression of Bcl-2. Thus, our transgenic animal model results
in Bcl-2–induced changes within the expected Sca-1–expressing T-
and B-lymphoid subsets of the adult hematopoietic system.
Bcl-2 overexpression results in increased numbers and
viability of Sca-1 and c-kit cells in the AGM
An overall examination of cell survival/death within the E11 AGM
region of Bcl-2 transgenic embryos by TUNEL staining revealed
no obvious changes as compared with wild-type sections. Hence, to
determine if Bcl-2 was indeed overexpressed in the AGM, RT-PCR
was performed on subdissected E11 AGM Bcl2 trangenic tissues.
Gene expression of Bcl-2, as well as antiapoptotic Bcl-x and
proapoptotic Bim, was tested. Figure 1D shows representative data
from one of several experiments. A 2- to 10-fold increase in Bcl-2
gene expression was consistently observed in the E11 transgenic
aorta, as compared with the nontransgenic aorta (Figure 1C). Also,
Bim expression is increased (approximately 1.5- to 4-fold), while
Bcl-x expression remained as in the nontransgenic tissue. Thus,
Bcl-2 is overexpressed within the transgenic E11 aorta (the
subregion in which the first HSCs are found).
To determine whether the overexpression of Bcl-2 disrupts the
normal balance of apoptosis and survival of phenotypically defined
populations of cells containing HSCs, fluorescence-activated cell
sorter (FACS) analysis with HSC surface markers c-kit and Sca-1
was performed on cells from E11 control and transgenic AGM
explant cultures. As shown in a representative profile of c-kit–
stained AGM cells (Figure 5A) (gated on nongranular cells), the
percentages of c-kit cells are increased by a factor of 1.5 in the
Bcl-2 transgenic tissues. This was confirmed in several independent
experiments, and the data are shown as fold change in percentage,
since the absolute number of cells in transgenic and nontransgenic
AGMs was comparable. The increase in percentage of c-kit and
Sca-1 cells in Bcl-2 E11 AGM explants ranged from 1.5- to
1.9-fold and 1.5- to 2.2-fold, respectively (Figure 2C). To confirm
that the increase in percentage of Sca-1 cells can in part be due to
Figure 4. Effects of Bcl-2 overexpression on adult mice and cells. (A) In vivo
survival curves of Bcl-2 transgenic mice and nontransgenic littermates. Adult mice of
7 to 22 weeks of age were subjected to a split dose of -irradiation of 10.5 Gy. Survival
of both Ln 479 (shown) and Ln 2 (not shown) transgenic mice and littermates was
checked daily over 30 days. Results are derived from 2 separate experiments for
each transgenic line. The number of mice irradiated at 10.5 Gy was n  10 for Ln 479
tg and n  12 for wt littermates. For other irradiation doses, 10 to 15 mice were used
per group (not shown). (B) Viable cell numbers of BM cells of Ln 479 transgenic
(Bcl-2) and a wild-type littermate (non-tg). Bcl-2 overexpression results in higher
viable cell numbers in vitro over a period of 11 days. Note that the scale on the y-axis
is logarithmic. These graphs show a representative experiment out of a total of 5
experiments (7 Bcl-2 tg and 7 wt littermates ranging 10 to 24 weeks of age). Error
bars indicate SEM.
Table 2. Percentages of cells obtained after annexin V and 7AAD
FACS analysis of BM from transgenic and nontransgenic mice
Annexin7AAD Annexin7AAD 7AAD
Nontransgenic 58.3 	 4.7 10.5 	 0.1 30.9 	 4.7
Bcl-2 91.0 	 2.5 3.7 	 0.3 4.4 	 1.3
Three transgenic mice (n  2 Ln 2 and n  1 Ln 479; mice aged 9 to 23 weeks)
and 3 nontransgenic littermates were used. Differences observed between the
transgenic and nontransgenic in the annexin7AAD, annexin7AAD, and 7AAD
subsets are statistically significant as determined by Student t test. Data are
presented as mean	 SEM.
Table 3. Lymphoid tissue and cell subset analysis of nontransgenic
and Bcl-2 transgenic adults
Nontransgenic Ln 479 Nontransgenic Ln 2
Body weight, g 29.4 	 5.7 29.4 	 5.8 31.4 	 4.0 32.0 	 4.7
Absolute cell numbers,
 107
Thymus 7.7 	 1.4 9.4 	 1.1 10.8 	 4.3 11.1 	 3.6
Spleen 14.7 	 1.6 31.9 	 6.4 11.4 	 1.1 37.3 	 1.9
Thymus cell subsets, %
CD4CD8 3.7 	 1.0 4.6 	 1.7 2.0, 3.8* 5.1 	 1.7
CD4CD8 83.5 	 3.6 75.6 	 4.2 87.8, 83.3* 70.9 	 5.2
CD4CD8 9.9 	 3.1 13.7 	 2.0 11.9, 9.2* 18.8 	 2.4
CD4CD8 3.0 	 0.6 6.1 	 0.7 1.0, 0.9* 5.2 	 1.4
Spleen cell subsets, 107
CD4 3.1 	 0.6 8.5 	 1.1 2.8, 1.1* 7.4 	 1.9
CD8 1.6 	 0.5 4.0 	 0.3 1.0, 0.5* 2.8 	 1.6
B220 10.0 	 0.7 21.4 	 5.1 8.0, 2.9* 18.6 	 2.7
Tissues were isolated from mice ranging in age from 10 to 20 weeks. Both male
and female mice are included in each of the groups. For the total thymus and spleen
cell counts, sample numbers are as follows: Ln 479 mice, n  6; their nontransgenic
littermates, n  6; Ln 2 mice, n  11; their nontransgenic littermates, n  7. For the
spleen and thymus subset cell determinations, n  3 except for nontransgenic Ln 2
control group. Values are given as mean	 SEM.
*Data represent 2 values (n  2).
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HSCs and not only to mesonephric cells, FACS analysis was
performed on subdissected E11 aorta explants. The percentage of
Sca-1 aorta cells increases 1.9-fold in the Bcl-2 transgenic aortas
as compared with nontransgenic aortas, strongly suggesting the
increase of HSCs. Moreover, similar increases in the percentages of
c-kit and Sca-1 cells in E11 transgenic liver explants were
observed (Figure 5A), strongly suggesting an increase in liver
HSCs in transgenic tissues. Thus, as shown with 2 independent
HSC markers, c-kit and Sca-1, overexpression of Bcl-2 results in
increased numbers of E11 AGM, aorta, and liver cell populations
containing phenotypically defined HSCs.
To examine whether the increase in c-kit and Sca-1 cells is
related to decreased apoptosis, we costained with annexin V and
performed cytometric analysis on the gated c-kit and Sca-1
fractions of 7AAD AGM, aorta, and liver cells. As shown in
Figure 5B, the percentage of annexin V cells in the c-kit fraction
of a Bcl-2 transgenic AGM explant is decreased 1.9-fold as
compared with wild-type AGM explants. This decrease ranged
from 1.9- to 2.6-fold in Bcl-2 AGM explants and from 1.1- to
1.2-fold in liver explants (Figure 5D). Furthermore, a decrease in
the percentage of annexin V cells (1.2- to 1.6-fold) was found in
the Sca-1 fraction of aorta explants (although this decrease is less
apparent in the histogram, owing to the isolation of fewer cells).
Thus, Bcl-2 overexpression leads to a quantitative increase in cell
populations containing phenotypically defined HSCs by decreasing
the number of these cells entering the apoptotic pathway in
midgestation hematopoietic tissues.
Hematopoietic stem cell activity is increased in the AGM
of Bcl-2–overexpressing embryos
To directly test whether Bcl-2 overexpression promotes the viability/
survival and increases the numbers of HSCs, in vivo hematopoietic
repopulation analyses were performed, both on adult BM cells and
on midgestation AGM and liver cells. Cells obtained from male
Bcl-2 transgenic and nontransgenic adults and E11 and E12
embryos were injected in limiting numbers in vivo into irradiated
adult female recipients. Recipients were analyzed for donor cell Y
chromosome contribution by peripheral blood DNA PCR at 4
months after injection. At a limiting dose of 104 cells, more HSC
activity was found in Bcl-2 transgenic BM (Figure 6A) than in
wild-type littermate controls. Frequency analysis was performed
(Table 4), and HSCs were found to be increased 2.6-fold (P 
 .03)
in the Bcl-2–overexpressing mice. Furthermore, by flow cytometry
on Bcl-2 transgenic BM (n  3), we found a 1.6- to 3.7-fold
(2.6 	 1.1) increase in the number of c-kit cells as compared with
nontransgenic BM (not shown). Thus, Bcl-2 overexpression in-
creases the number of BM HSCs.
Limiting dilution in vivo transplantation experiments with
AGM and liver cells from Bcl-2 transgenic and wild-type male
embryos revealed that the HSC activity of E11 Bcl-2 transgenic
AGM cells (Figure 6B) was higher (10 repopulated of 25 recipi-
ents) than in transgenic littermate controls (only 2 of 19 recipients
repopulated). Engraftment was high level (up to 100% donor
derived), long term, and multilineage (not shown). By E12, HSC
activity in transgenic AGMs was similar to that of the E12
nontransgenic AGM, but this may be due to saturating numbers of
HSCs in the injected dose. Bcl-2 transgenic E12 liver also showed
some increases in HSC activity when compared with nontransgenic
liver at limiting injection doses (Figure 6C). Frequency analysis
(Table 4) revealed that HSC numbers were significantly increased
in the E11 AGM by a factor of 4.5 (P 
 .02). Thus, Bcl-2
overexpression increases the number of functionally repopulating
AGM HSCs.
To further check the potency of these midgestation HSCs,
limiting doses of BM cells from the primary Bcl-2 transgenic and
nontransgenic AGM- and liver-engrafted recipients were injected
into secondary recipients. Bcl-2 transgenic secondary transplanted
AGM cells showed potent HSC activity (Figure 6B, right side of
Figure 5. Increased numbers and viability of c-kit and Sca-1 cells in Bcl-2–overexpressing AGM and liver. E11 AGM, aorta, and liver tissues from Bcl-2 transgenic and
nontransgenic embryos were dissected and cultured as explants for 3 to 4 days, during which time the embryos were genotyped. Tissues from embryos with a similar genotype
were pooled, and single-cell suspensions were stained with antibodies specific for c-kit or Sca-1 and with annexin V and 7AAD. (A) Representative FACS plots for c-kit– and
Sca-1–stained cells (top and bottom rows, respectively) within the 7AAD fraction of wild-type (WT) and Bcl-2–overexpressing AGM and aorta tissues, respectively. Side
scatter (SSC) is shown on the x-axis and fluorescent antibody staining on the y-axis. Percentages of c-kit and Sca-1 cells are shown for the gated region (HSCs are found
within the nongranular side scatter). (B) Within the c-kit and Sca-1 fractions of AGM and aorta tissues, the percentage of annexin V cells was determined (indicating the
percentage of cells entering the apoptotic pathway). Representative histogram plots are shown with indicated percentages of annexin V cells in the c-kit (top row) or Sca-1
(bottom row) cell fractions, respectively, in the AGM or subdissected aorta. Bcl-2–overexpressing tissues (right panels) contain less annexin V cells within the c-kit and
Sca-1 fraction. (C) Overview of the fold changes (increases) in percentages of c-kit and Sca-1 cells and (D) fold changes (decreases) in percentages of annexin V cells
within the c-kit and Sca-1 fractions of Bcl-2 transgenic E11 AGM, aorta, or liver cells as compared with wild-type cells. Percentages were determined as indicated in panels A
and B. Results are shown for 3 experiments with Sca-1 and annexin V, 3 experiments with c-kit and annexin V, and 2 experiments with E11 aorta cells. Each bar in the graph
represents an independent experiment containing embryos from 1 to 3 litters. From each experiment, several samples (each contained a pool of cells from 1 to 3 tissues) were
measured, and the average of these samples is shown. Total number of events analyzed ranges from 8  104 to 2  105.
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panel), while nontransgenic cells provided no engraftment (com-
bined data of transgenic secondary transplants: 7 repopulated of 10
transplanted as compared with nontransgenic transplants, 0 of 4).
Similarly, Bcl-2 transgenic secondary transplanted liver cells
showed HSC activity, while nontransgenic liver did not give rise to
donor cell engraftment (Figure 6C, right side of panel). Thus, these
transplantation data demonstrate that Bcl-2–overexpressing AGM
and liver tissues possess higher HSC activity and self-renewal
ability than nontransgenic tissues, strongly suggesting that apoptosis
plays a role in the regulation of HSCs in the midgestation mouse.
Discussion
It has been widely accepted that a tight quantitative control of
HSCs is essential in maintaining the appropriate and stable
representation of progenitors and differentiated cells in the adult
hematopoietic hierarchy. Because the blood system is highly
dynamic, responds rapidly to trauma, and also constantly replen-
ishes itself, cell survival and apoptosis play an important role in
regulation of this tissue system. Our results show that, during
development of the hematopoietic system within the embryo, these
processes also appear to play a role.
It can be implied from the observed HSC increases in our Ly-6E
(Sca-1) Bcl-2 transgenic mice that components of the Bcl-2
pathway leading to cell survival are intact and functionally relevant
in these cells. Until our investigation, it was not known whether
Bcl-2 is normally expressed in this region. Our immunostainings
have shown that Bcl-2 protein is expressed in the midgestation
AGM and, furthermore, by TUNEL analysis, that apoptosis is
ongoing in this region. Bcl-2 transcripts are found in both the aorta
and the UGRs. While TUNEL foci are found in the mesonephric
tubules (indicating apoptosis), it appears that the apoptosis occur-
ring in the region surrounding the dorsal aorta is limited to single
cells. These data suggest that there is a tight regulation of apoptosis
in this region, and we postulate that, in addition to Bcl-2, other
apoptotic regulators play a role in the balance between cell survival
and apoptosis in the AGM.
We have found expression of the Bcl-x antiapoptotic regulator
and the Bim proapoptotic regulator in the midgestation aorta and
UGRs. Since the results of other researchers in adult hematopoietic
cell subsets and tissues21 show only slight overlap in Bcl-2 and
Bcl-x in vivo expression patterns, these molecules may be ex-
pressed in different AGM cell subsets. Indeed, gene-targeted
mutant mice show different phenotypes.12,22,44 Bcl-2–deficient mice
complete embryonic development and show increased apoptosis in
lymphocyte populations, and Bcl-x–deficient mice die around E13
with extensive apoptosis of hematopoietic cells in the fetal liver.
Interestingly, recent data show that concomitant loss of the
proapoptotic Bim gene and the antiapoptotic Bcl-2 gene allows
normal physiologic functions, and thus, Bim counterbalances Bcl-2
activity.45 Moreover, Bim expression has been found in several
hematopoietic cell lines,46,47 and Bim up-regulation correlates with
increased apoptosis induced in E17 fetal liver cells upon hematopoi-
etic growth factor withdrawal.48 Therefore, there are important
roles for Bcl-2, Bcl-x, and Bim in regulating apoptosis in hemato-
poietic cells, and the intracellular ratios of these and other
proapoptotic and antiapoptotic proteins are expected to play a
critical role in setting the balance between cellular life or death.
Semiquantitative transcriptional analysis of these 3 genes in the
normal and Bcl-2–overexpressing AGM, aorta, UGRs, and liver
suggests that the balance of proapoptotic and antiapoptotic mol-
ecules is also important during midgestation hematopoiesis. When
Figure 6. Increased HSC activity in the bone marrow, AGM, and liver of Bcl-2–overexpressing transgenic animals. (A) HSC activity in the BM of Bcl-2–overexpressing
mice. Whole BM from a male Ln 479 transgenic (tg) and a nontrangenic (wt) littermate was injected at different limiting doses (103, 104, and 105 cells) together with 105 female
BM cells into irradiated female recipients. At 4 months after transplantation, the peripheral blood of the recipient was analyzed in a semiquantitative manner for male donor
hematopoietic cells. Black triangles represent individual recipients engrafted with Bcl-2 BM, and gray circles indicate individual recipients engrafted with wt BM. Results of
competitive repopulation experiments for Ln 479 transgenic and nontransgenic littermates are shown. A greater than 10% engraftment level in the peripheral blood was used as
the criterion for positive HSC repopulation. Ln2 transgenic BM gave similar results (not shown). (B-C) Transplantations were performed with E11 AGM, E12 AGM Ln 479
transgenic (f; panel B), and E12 liver cells (f; panel C), as well as nontransgenic control cells (u). The combined results of 2 independent transplantation experiments show
the percentage repopulated recipients (y-axis) and the number of mice positive/the number of total mice injected for each group. ee indicates embryo equivalents injected; and
ND, not done. All recipients considered positive at more than 4 months after transplantation showed donor-derived cell engraftment levels exceeding 10% by semiquantitative
PCR. In general, a higher percentage of repopulated recipients is seen with Bcl-2 transgenic midgestation AGM and liver cells than with wild-type littermate cells. Results of
secondary transplantations are shown on the right. BM cells from primary recipients injected with E11 AGM, E12 AGM, and E12 liver were transplanted in limiting dilutions into
irradiated adult secondary recipients. The percentage of repopulated recipients and the number of mice positive/the number of total mice injected are shown for each group.
The BM cells of the primary recipients injected with E11 AGM, E12 AGM, and E12 liver cells that were used for secondary transplantation were 75% to 100% repopulated by
donor-derived cells. Results were obtained at more than 4 months after transplantation by PCR analysis of peripheral blood DNA. Again, a higher percentage of repopulated
recipients is seen with Bcl-2 transgenic as compared with wild-type littermate cells.
Table 4. Frequency analysis of HSCs in embryonic and adult
hematopoietic tissues
Tissue
transplanted
Nontransgenic Bcl-2 trangenic
HSC frequency HSC/ee HSC frequency HSC/ee
E11 AGM 1/2.7  105 0.37 1/0.6  105 1.70*
E12 AGM 1/0.4  105 2.54 1/0.4  105 2.78
E12 liver 1/0.017  105 58.8 1/0.013  105 76.9
Bone marrow 1/6.28  104 NA 1/2.31  104 NA
HSC frequencies were determined from the primary transplantation data in
Figure 6 and were calculated by means of L-Calc software (StemCell Technologies,
Vancouver, BC, Canada). ee indicates embryo equivalent; and NA, not applicable.
*Statistical significance; P 
 .02.
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Bcl-2 is overexpressed in the aorta in transgenic embryos, a
concomitant increase in Bim, but not Bcl-x, is observed. How this
balance is achieved at the transcriptional level is unknown. Further
studies should determine whether these 3 molecules (or other
combinations) are expressed in the same population/subset of
AGM cells and the precise balance between these proapoptotic and
antiapoptotic molecules that leads to increased HSC activity in the
mouse embryo.
We have shown here that Bcl-2 overexpression increases the
numbers of c-kit and Sca-1 cells in the AGM, decreases their
entry into the apoptotic pathway, and, more important, increases
the numbers of functional HSCs beginning at midgestation in the
AGM. HSC activity was significantly increased in the E11 AGMs
from Sca-1 Bcl-2 transgenic embryos (4.5-fold increase; P 
 .02).
Such an increase was less apparent in transgenic E12 AGM and
liver. However, when secondary transplantations were performed
to confirm the self-renewal ability of AGM and liver HSCs,
increased HSC activity was observed in the Bcl-2 transgenic
primary BM as compared with the nontransgenic recipients,
suggesting that saturating numbers of HSCs were present in the
primary Bcl-2 engrafted recipient. Thus, Bcl-2 overexpression
affects the repopulating activity of the first AGM and liver HSCs.
Whether Bcl-2 overexpression has a direct effect only on HSC
number or has several related effects, such as enhancing engraft-
ment through survival and/or influencing the cell cycle status of
HSCs (as for adult BM HSCs), is yet to be determined. Importantly,
whatever the effect of Bcl-2 overexpression on HSCs, these cells
are normal, renew themselves, and contribute to long-term, multi-
lineage repopulation. The fact that increased HSC numbers are
found in the AGM, liver, and adult BM suggests the intriguing
possibility that HSCs undergo apoptosis more often and much
earlier than was previously appreciated.
Finally, in examining the validity of our Bcl-2 overexpression
transgenic mouse model in the adult hematopoietic system, we
found that Bcl-2 overexpression occurs in the tissues and hemato-
poietic cells that are normally expected to express Sca-1.31-35
Sca-1–directed Bcl-2 overexpression affects adult hematopoietic
cells under both normal and stressful conditions, most likely by
preventing them from entering the apoptotic pathway. As expected
from the previous results of others,24,28 Sca-1–directed Bcl-2
overexpression results in radio-protection and in increases of BM
HSC activity (as determined by in vivo transplantation). Frequency
analysis revealed that BM HSC numbers were significantly in-
creased in Bcl-2 transgenic adults by a factor of 2.7. This increased
BM HSC activity may be related to a lower susceptibility of the
transgenic HSCs to entering into apoptosis during the engraftment
of the recipient. Several studies have reported that Bcl-2 influences
the cell cycle by blocking the transition from G1 to S-G2-M.49,50
Since there is a correlation between the cell cycle status of HSCs
and their ability to home to the recipient BM (see Jetmore et al51
and references therein), it is possible that altered cell cycle profiles
could result in the facilitated engraftment we observed for Sca-1
Bcl-2–overexpressing HSCs. Nonetheless, the Bcl-2–related in-
crease in HSC activity is also due to an increase in the absolute
number of HSCs, since we have found more c-kit cells in Bcl-2
transgenic BM (1.6- to 3.7-fold increase). This is in accordance
with the findings of Domen et al9 in H2K-Bcl2 mice in which the
c-kit lineage-negative (c-kitlin) HSCs are increased 2.4-fold as
compared with wild-type mice. Given the notion that Bcl-2–
overexpressing HSCs enter into apoptotic stages at a lower
frequency and remain viable for longer periods of time, it may now
be possible to isolate cell lines of this difficult-to-culture Sca-1
hematopoietic subset from the AGM and adult BM. Such cell lines
would greatly facilitate molecular analyses of developmentally
specific HSC genetic programs.
Taken together, our studies show that antiapoptotic and proapop-
totic processes are intact, active, and functioning in the earliest
expanding HSCs in the AGM region of the mouse embryo and that
apoptosis/cell survival plays an important role in these first HSCs.
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